MA39155A1 - Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol - Google Patents
Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérolInfo
- Publication number
- MA39155A1 MA39155A1 MA39155A MA39155A MA39155A1 MA 39155 A1 MA39155 A1 MA 39155A1 MA 39155 A MA39155 A MA 39155A MA 39155 A MA39155 A MA 39155A MA 39155 A1 MA39155 A1 MA 39155A1
- Authority
- MA
- Morocco
- Prior art keywords
- formoterol
- combination
- glycopyrronium bromide
- aerosol solution
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
- A61M2039/226—Spindles or actuating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Filling Or Discharging Of Gas Storage Vessels (AREA)
- Steroid Compounds (AREA)
Abstract
L'invention concerne une composition de solution d'aérosol, conçue pour être utilisée avec un aérosol-doseur mis sous pression, comportant du bromure de glycopyrronium et du formotérol, ou un sel de ceux-ci ou un solvate dudit sel, facultativement en combinaison avec un ou plusieurs principes actifs supplémentaires, stabilisée par une quantité choisie d'un acide minéral, la quantité de produit de dégradation n-(3-bromo)-[2-hydroxy-5-[l-hydroxy-2-[l-(4- méthoxyphényl) propan-2-ylamino]éthyl] phényl] formamide étant inférieure à la limite de quantification, lorsqu'elle est stockée dans des conditions accélérées à 25 °c et à une humidité relative (rh) de 60 % pendant 6 mois dans une boîte recouverte intérieurement par une résine comportant un polymère d'éthylène-propylène fluoré (fep). Le ou les principes actifs facultatifs peuvent être un corticostéroïde d'inhalation choisi parmi le dipropionate de béclométasone, le budésonide ou son épimère 22r, le ciclésonide, le flunisolide, le propionate de fluticasone, le furoate de fluticasone, le furoate de mométasone, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13199784 | 2013-12-30 | ||
| PCT/EP2014/079259 WO2015101576A1 (fr) | 2013-12-30 | 2014-12-23 | Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39155A1 true MA39155A1 (fr) | 2017-04-28 |
Family
ID=49886777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39155A MA39155A1 (fr) | 2013-12-30 | 2016-06-28 | Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US10596113B2 (fr) |
| EP (3) | EP3089735B1 (fr) |
| JP (2) | JP6563950B2 (fr) |
| KR (2) | KR101861117B1 (fr) |
| CN (2) | CN111150728B (fr) |
| AR (2) | AR098982A1 (fr) |
| AU (1) | AU2014375301C1 (fr) |
| BR (1) | BR112016014583B1 (fr) |
| CA (1) | CA2935305C (fr) |
| CL (1) | CL2016001653A1 (fr) |
| CY (1) | CY1120668T1 (fr) |
| DK (1) | DK3089735T3 (fr) |
| EA (1) | EA033227B1 (fr) |
| ES (1) | ES2687345T3 (fr) |
| GE (1) | GEP20186855B (fr) |
| HR (1) | HRP20181551T1 (fr) |
| HU (1) | HUE039513T2 (fr) |
| IL (1) | IL246498B (fr) |
| LT (1) | LT3089735T (fr) |
| MA (1) | MA39155A1 (fr) |
| MX (1) | MX368835B (fr) |
| MY (1) | MY182861A (fr) |
| PE (1) | PE20160997A1 (fr) |
| PH (1) | PH12016501268B1 (fr) |
| PL (1) | PL3089735T3 (fr) |
| PT (1) | PT3089735T (fr) |
| RS (1) | RS57687B1 (fr) |
| SA (1) | SA516371427B1 (fr) |
| SG (1) | SG11201605311UA (fr) |
| SI (1) | SI3089735T1 (fr) |
| TN (1) | TN2016000261A1 (fr) |
| TW (1) | TWI660747B (fr) |
| UA (1) | UA117845C2 (fr) |
| WO (1) | WO2015101576A1 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012015334A2 (pt) * | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| SG181870A1 (en) | 2009-12-23 | 2012-07-30 | Chiesi Farma Spa | Aerosol formulation for copd |
| EP2515855B3 (fr) | 2009-12-23 | 2023-05-03 | Chiesi Farmaceutici S.p.A. | Polythérapie pour la COPD |
| RS57687B1 (sr) * | 2013-12-30 | 2018-11-30 | Chiesi Farm Spa | Pod pritiskom stabilan aerosolni rastvor kompozicije glikopironijum bromida i kombinacije formoterola |
| GEAP201814192A (en) * | 2013-12-30 | 2018-02-26 | Chiesi Farm Spa | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
| ES2796177T5 (es) | 2015-12-04 | 2024-10-29 | Mexichem Fluor Sa De Cv | Composición farmacéutica |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| GEP20217239B (en) | 2016-09-19 | 2021-03-25 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| CN107233311B (zh) * | 2017-06-27 | 2020-12-04 | 长风药业股份有限公司 | 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法 |
| EP3860580A4 (fr) * | 2018-10-01 | 2022-07-20 | Kindeva Drug Delivery L.P. | Formulation et cartouches d'aérosol, inhalateurs et analogues contenant la formulation |
| WO2020084549A1 (fr) * | 2018-10-25 | 2020-04-30 | Glenmark Specialty S.A. | Composition de nébulisation comprenant du glycopyrrolate et du formotérol |
| EP3996672A1 (fr) * | 2019-07-12 | 2022-05-18 | Kindeva Drug Delivery L.P. | Formulation d'aérosol, cartouche et inhalateur contenant la formulation, et procédé d'utilisation |
| AU2019477296A1 (en) | 2019-12-02 | 2022-04-14 | Chiesi Farmaceutici S.P.A. | Stainles steel can for pressurised metered dose inhalers |
| NZ789880A (en) * | 2020-01-28 | 2026-01-30 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| IL295269A (en) * | 2020-02-20 | 2022-10-01 | Chiesi Farm Spa | Inhalers with a measured dose under pressure that include the composition of pharmacy buffers |
| US20230270754A1 (en) | 2020-07-31 | 2023-08-31 | Chemo Research, S.L. | Combination therapy for inhalation administration |
| CN112051346A (zh) * | 2020-09-24 | 2020-12-08 | 珠海瑞思普利生物制药有限公司 | 一种同时测定茚达特罗和格隆溴铵含量的hplc方法 |
| US20230277451A1 (en) | 2020-10-09 | 2023-09-07 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
| US20250009653A1 (en) * | 2021-09-08 | 2025-01-09 | Kindeva Drug Delivery L.P. | Propellants for anticholinergic agents in pressurized metered dose inhalers |
| US20250058063A1 (en) * | 2021-12-21 | 2025-02-20 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
| CN116338014A (zh) * | 2021-12-23 | 2023-06-27 | 上海医药工业研究院有限公司 | 一种吸入用药物组合物的组分分离检测方法 |
| EP4531921A1 (fr) | 2022-05-27 | 2025-04-09 | Chiesi Farmaceutici S.p.A. | Formulation pharmaceutique pour aérosol-doseur sous pression |
| EP4531922A1 (fr) | 2022-05-27 | 2025-04-09 | Chiesi Farmaceutici S.p.A. | Formulation pharmaceutique pour aérosol-doseur pressurisé |
| EP4531920A1 (fr) | 2022-05-27 | 2025-04-09 | Chiesi Farmaceutici S.p.A. | Formulation pharmaceutique pour aérosol-doseur sous pression |
| CN117679423A (zh) | 2022-09-05 | 2024-03-12 | 立生医药(苏州)有限公司 | 预防或治疗呼吸系统疾病的吸入用药物组合物 |
| TW202600144A (zh) * | 2024-02-23 | 2026-01-01 | 瑞典商阿斯特捷利康公司 | Copd之三重組合療法 |
| WO2026006658A1 (fr) | 2024-06-27 | 2026-01-02 | Lupin Inc. | Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression |
| GR1011131B (el) * | 2025-05-15 | 2026-02-06 | Elpen Ανωνυμος Εταιρεια Φαρμακευτικη Βιομηχανια, | Φαρμακευτικο διαλυμα βεκλομεθαζονης και φορμοτερολης για εισπνοη σε περιεκτη υπο πιεση με τροποιημενη εσωτερικη επιφανεια |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| JP4672143B2 (ja) | 1998-08-04 | 2011-04-20 | ヤゴテック アーゲー | 医薬用エーロゾル製剤 |
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| AU2000250701B2 (en) * | 2000-05-22 | 2004-07-01 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| EP1241113A1 (fr) * | 2001-03-12 | 2002-09-18 | CHIESI FARMACEUTICI S.p.A. | Inhalateur avec des moyens pour améliorer la stabilité chimique des solutions d'aerosol médicinales qu'il contient |
| EP1321159A1 (fr) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser |
| US20040126325A1 (en) * | 2002-03-12 | 2004-07-01 | David Lewis | Medicinal aerosol solution formulation products with improved chemical stability |
| ES2309705T3 (es) | 2004-02-06 | 2008-12-16 | MEDA PHARMA GMBH & CO. KG | Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias. |
| ES2413011T3 (es) | 2004-02-06 | 2013-07-15 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC |
| CN100457087C (zh) * | 2004-02-27 | 2009-02-04 | 奇斯药制品公司 | 用于加压计量吸入器的稳定的药用溶液制剂 |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| BRPI0510852A (pt) * | 2004-05-13 | 2007-11-27 | Chiesi Farma Spa | produtos medicinais em formulação aerossol com estabilidade quìmica aprimorada |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| EP2484382A1 (fr) | 2005-03-30 | 2012-08-08 | Schering Corporation | Médicament à base d'un inhibiteur de la phosphodiestérase IV sous une forme adaptée à l'inhalation |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| EP2201934A1 (fr) * | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Produits de formule d'aérosol de tiotropium avec stabilité chimique améliorée |
| AU2010258751A1 (en) * | 2009-06-09 | 2012-02-02 | Sunovion Respiratory Development Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| BR112012015334A2 (pt) * | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| EP2515855B3 (fr) | 2009-12-23 | 2023-05-03 | Chiesi Farmaceutici S.p.A. | Polythérapie pour la COPD |
| SG181870A1 (en) * | 2009-12-23 | 2012-07-30 | Chiesi Farma Spa | Aerosol formulation for copd |
| KR20120106753A (ko) | 2009-12-23 | 2012-09-26 | 키에시 파르마슈티시 엣스. 피. 에이. | Ｃｏｐｄ용 에어로졸 제제 |
| BR112013005283A2 (pt) | 2010-09-06 | 2019-09-24 | Chiesi Farm Spa | atuador de inalador dosimetrado, de inalador dosimetrado e uso de um atuador |
| RU2013155903A (ru) * | 2011-05-17 | 2015-06-27 | Перл Терапьютикс, Инк. | Композиции, способы и устройства для респираторной доставки двух или более активных средств |
| KR20150048727A (ko) | 2012-08-29 | 2015-05-07 | 키에시 파르마슈티시 엣스. 피. 에이. | 에어로졸 흡입 장치 |
| RS57687B1 (sr) * | 2013-12-30 | 2018-11-30 | Chiesi Farm Spa | Pod pritiskom stabilan aerosolni rastvor kompozicije glikopironijum bromida i kombinacije formoterola |
| GEAP201814192A (en) * | 2013-12-30 | 2018-02-26 | Chiesi Farm Spa | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
-
2014
- 2014-12-23 RS RS20181112A patent/RS57687B1/sr unknown
- 2014-12-23 AU AU2014375301A patent/AU2014375301C1/en active Active
- 2014-12-23 EP EP14825154.9A patent/EP3089735B1/fr active Active
- 2014-12-23 UA UAA201606910A patent/UA117845C2/uk unknown
- 2014-12-23 SI SI201430881T patent/SI3089735T1/sl unknown
- 2014-12-23 EA EA201691126A patent/EA033227B1/ru active Protection Beyond IP Right Term
- 2014-12-23 SG SG11201605311UA patent/SG11201605311UA/en unknown
- 2014-12-23 HR HRP20181551TT patent/HRP20181551T1/hr unknown
- 2014-12-23 LT LTEP14825154.9T patent/LT3089735T/lt unknown
- 2014-12-23 HU HUE14825154A patent/HUE039513T2/hu unknown
- 2014-12-23 DK DK14825154.9T patent/DK3089735T3/en active
- 2014-12-23 MY MYPI2016001207A patent/MY182861A/en unknown
- 2014-12-23 JP JP2016561079A patent/JP6563950B2/ja active Active
- 2014-12-23 EP EP19175726.9A patent/EP3566694A1/fr active Pending
- 2014-12-23 GE GEAP201814191A patent/GEP20186855B/en unknown
- 2014-12-23 EP EP18171127.6A patent/EP3384898A1/fr active Pending
- 2014-12-23 PL PL14825154T patent/PL3089735T3/pl unknown
- 2014-12-23 CN CN202010180583.6A patent/CN111150728B/zh active Active
- 2014-12-23 MX MX2016008594A patent/MX368835B/es active IP Right Grant
- 2014-12-23 CA CA2935305A patent/CA2935305C/fr active Active
- 2014-12-23 WO PCT/EP2014/079259 patent/WO2015101576A1/fr not_active Ceased
- 2014-12-23 CN CN201480071526.7A patent/CN105848641B/zh active Active
- 2014-12-23 TN TN2016000261A patent/TN2016000261A1/en unknown
- 2014-12-23 BR BR112016014583-6A patent/BR112016014583B1/pt active IP Right Grant
- 2014-12-23 ES ES14825154.9T patent/ES2687345T3/es active Active
- 2014-12-23 PE PE2016000968A patent/PE20160997A1/es unknown
- 2014-12-23 KR KR1020167020695A patent/KR101861117B1/ko active Active
- 2014-12-23 KR KR1020187007444A patent/KR101861119B1/ko active Active
- 2014-12-23 PT PT14825154T patent/PT3089735T/pt unknown
- 2014-12-29 TW TW103146043A patent/TWI660747B/zh active
- 2014-12-29 AR ARP140104938A patent/AR098982A1/es not_active Application Discontinuation
- 2014-12-30 US US14/585,533 patent/US10596113B2/en active Active
-
2016
- 2016-06-28 PH PH12016501268A patent/PH12016501268B1/en unknown
- 2016-06-28 CL CL2016001653A patent/CL2016001653A1/es unknown
- 2016-06-28 MA MA39155A patent/MA39155A1/fr unknown
- 2016-06-28 SA SA516371427A patent/SA516371427B1/ar unknown
- 2016-06-28 IL IL246498A patent/IL246498B/en active IP Right Grant
- 2016-06-29 US US15/196,318 patent/US10617638B2/en active Active
-
2018
- 2018-09-11 CY CY181100949T patent/CY1120668T1/el unknown
-
2019
- 2019-07-25 JP JP2019136785A patent/JP6823118B2/ja active Active
-
2023
- 2023-08-17 AR ARP230102185A patent/AR130239A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39155A1 (fr) | Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol | |
| MA39154A1 (fr) | Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol | |
| AR081540A1 (es) | Proceso para proveer particulas con cargas electroestaticas reducidas | |
| MX2021009476A (es) | Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
| RU2012142295A (ru) | Способ приготовления частиц носителя для сухих порошков для ингаляции | |
| BR112022014228A2 (pt) | Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada | |
| HRP20140864T1 (hr) | Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergiäśke agoniste | |
| NZ600789A (en) | Aerosol formulation for copd | |
| JP2016510012A5 (fr) | ||
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| HK1215388A1 (zh) | 可吸入药用组合物和含有该药用组合物的吸入器装置 | |
| CA3193038A1 (fr) | Formulation pharmaceutique pour inhalateur doseur pressurise | |
| JP2014527056A5 (fr) | ||
| CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion | |
| JP2011500731A5 (fr) | ||
| TH171992A (th) | องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล | |
| ZA202108150B (en) | An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate | |
| TH171993A (th) | องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล | |
| PL432374A1 (pl) | Nowy inhalacyjny system terapeutyczny dostarczający zredukowaną ilość propionianu flutikazonu i salmeterolu o zwiększonej skuteczności i profilu bezpieczeństwa | |
| NZ786610A (en) | Stainless steel can for pressurised metered dose inhalers | |
| TR201716233A2 (tr) | Solunum yolları hastalıklarının tedavisi için birden fazla etken madde içeren farmasötik bileşim. |